103.33
price up icon0.33%   0.24
 
loading
Schlusskurs vom Vortag:
$103.09
Offen:
$103.16
24-Stunden-Volumen:
318.92K
Relative Volume:
0.29
Marktkapitalisierung:
$206.46B
Einnahmen:
$49.94B
Nettoeinkommen (Verlust:
$17.60B
KGV:
27.78
EPS:
3.72
Netto-Cashflow:
$12.51B
1W Leistung:
+0.03%
1M Leistung:
-10.62%
6M Leistung:
+0.58%
1J Leistung:
+7.32%
1-Tages-Spanne:
Value
$103.03
$103.50
1-Wochen-Bereich:
Value
$102.40
$103.50
52-Wochen-Spanne:
Value
$92.35
$120.92

Novartis Ag Adr Stock (NVS) Company Profile

Name
Firmenname
Novartis Ag Adr
Name
Telefon
-
Name
Adresse
-
Name
Mitarbeiter
76,057
Name
Twitter
@novartis
Name
Nächster Verdiensttermin
2024-10-29
Name
Neueste SEC-Einreichungen
Name
NVS's Discussions on Twitter

Vergleichen Sie NVS mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
NVS 103.37 206.46B 49.94B 17.60B 12.51B 3.72
LLY 738.36 693.54B 40.86B 8.37B -2.28B 5.4193
NVO 101.75 465.74B 39.36B 13.79B 9.83B 2.4077
JNJ 153.09 353.35B 87.70B 14.68B 19.03B 13.47
ABBV 167.72 294.70B 55.53B 5.12B 15.62B 3.65
MRK 97.05 248.54B 63.17B 12.15B 14.84B 1.80

Novartis Ag Adr Stock (NVS) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-09-05 Herabstufung Goldman Buy → Neutral
2024-09-03 Herabstufung Jefferies Buy → Hold
2024-07-19 Herabstufung Deutsche Bank Buy → Hold
2024-05-30 Eingeleitet Goldman Buy
2024-02-23 Eingeleitet BMO Capital Markets Market Perform
2024-01-23 Eingeleitet Morgan Stanley Equal-Weight
2024-01-16 Fortgesetzt UBS Buy
2023-12-18 Herabstufung HSBC Securities Buy → Hold
2023-09-25 Hochstufung Morgan Stanley Underweight → Equal-Weight
2023-07-14 Eingeleitet HSBC Securities Buy
2023-04-26 Hochstufung Deutsche Bank Hold → Buy
2023-03-27 Hochstufung Deutsche Bank Sell → Hold
2023-01-26 Herabstufung Citigroup Buy → Neutral
2022-12-05 Hochstufung Stifel Hold → Buy
2022-09-15 Herabstufung Credit Suisse Neutral → Underperform
2022-09-14 Herabstufung Berenberg Buy → Hold
2022-05-09 Herabstufung Wolfe Research Outperform → Peer Perform
2022-01-10 Fortgesetzt Citigroup Buy
2021-12-14 Herabstufung Redburn Buy → Neutral
2021-12-06 Herabstufung Exane BNP Paribas Outperform → Neutral
2021-12-03 Herabstufung Bryan Garnier Buy → Neutral
2021-09-20 Herabstufung Deutsche Bank Hold → Sell
2021-03-22 Eingeleitet Bernstein Mkt Perform
2021-03-10 Herabstufung Argus Buy → Hold
2021-02-01 Herabstufung Cowen Outperform → Market Perform
2021-01-15 Eingeleitet Deutsche Bank Buy
2020-09-29 Eingeleitet Berenberg Buy
2020-09-10 Hochstufung UBS Neutral → Buy
2020-09-01 Hochstufung Morgan Stanley Equal-Weight → Overweight
2020-06-15 Hochstufung Citigroup Neutral → Buy
2020-03-10 Hochstufung Morgan Stanley Underweight → Equal-Weight
2020-02-25 Herabstufung Guggenheim Buy → Neutral
2019-04-25 Hochstufung Guggenheim Neutral → Buy
2019-04-25 Hochstufung Liberum Hold → Buy
2019-04-10 Herabstufung Morgan Stanley Equal-Weight → Underweight
2019-01-02 Herabstufung JP Morgan Neutral → Underweight
2018-12-11 Fortgesetzt Jefferies Buy
2018-10-09 Eingeleitet Guggenheim Neutral
2018-09-10 Hochstufung BofA/Merrill Underperform → Buy
2018-05-29 Herabstufung HSBC Securities Buy → Hold
2018-05-25 Hochstufung Credit Suisse Underperform → Neutral
2018-01-25 Bestätigt Leerink Partners Outperform
2017-12-06 Herabstufung BofA/Merrill Neutral → Underperform
2017-07-26 Hochstufung Morgan Stanley Underweight → Overweight
2017-07-05 Herabstufung Credit Suisse Neutral → Underperform
2017-03-09 Eingeleitet Liberum Buy
Alle ansehen

Novartis Ag Adr Aktie (NVS) Neueste Nachrichten

pulisher
Nov 20, 2024

Weekly Upgrades and Downgrades - InvestorPlace

Nov 20, 2024
pulisher
Nov 20, 2024

Inside the Market Dominance of the Top 10 Pharma Giants - Value the Markets

Nov 20, 2024
pulisher
Nov 19, 2024

Novartis ranks first in 2024 Access to Medicine Index - GlobeNewswire Inc.

Nov 19, 2024
pulisher
Nov 06, 2024

Novo Nordisk A/S (NVO) Stock Price, News, Quote & History - Yahoo Finance

Nov 06, 2024
pulisher
Nov 01, 2024

Our commitment to ethical and responsible use of Artificial Intelligence (AI) - Novartis

Nov 01, 2024
pulisher
Oct 29, 2024

Novartis on Pace for Largest Percent Decrease Since March 2021 — Data Talk - Morningstar

Oct 29, 2024
pulisher
Oct 29, 2024

Novartis Ag (NVS) Q3 2024 Earnings Call Transcript - Barchart

Oct 29, 2024
pulisher
Oct 29, 2024

Chemical Biology in Biomedical Research - Novartis

Oct 29, 2024
pulisher
Oct 29, 2024

Radioligand therapy: delivering now, building for the future - Novartis

Oct 29, 2024
pulisher
Oct 29, 2024

Novartis at ASH - Novartis

Oct 29, 2024
pulisher
Oct 29, 2024

Novartis 2022 Financial Results - Novartis

Oct 29, 2024
pulisher
Oct 29, 2024

Novartis Financial Results – Q2 2023 - Novartis

Oct 29, 2024
pulisher
Oct 29, 2024

Translational medicine research at Novartis - Novartis

Oct 29, 2024
pulisher
Oct 29, 2024

Novartis Financial Results – Q2 2024 - Novartis

Oct 29, 2024
pulisher
Oct 29, 2024

Inclusivity - Novartis

Oct 29, 2024
pulisher
Oct 29, 2024

Collaborations - Novartis

Oct 29, 2024
pulisher
Oct 25, 2024

Biliary Tract Cancer Market Research Report 2024-2030 with Analyst Recommendations - GlobeNewswire Inc.

Oct 25, 2024
pulisher
Oct 23, 2024

South Africa Central Nervous System Therapeutic Market Size & Outlook, 2028 - Grand View Research

Oct 23, 2024
pulisher
Oct 22, 2024

5 Large Drug Stocks Likely To Outpace Q3 Earnings Estimates - Barchart

Oct 22, 2024
pulisher
Oct 21, 2024

Germany Central Nervous System Therapeutic Market Size & Outlook, 2028 - Grand View Research

Oct 21, 2024
pulisher
Oct 18, 2024

21 Best Healthcare Companies to Invest In - Morningstar

Oct 18, 2024
pulisher
Oct 17, 2024

1 Healthcare Giant That Isn't Jumping on the GLP-1 Bandwagon, and Why That Could Be a Great Move - sharewise

Oct 17, 2024
pulisher
Oct 16, 2024

Saudi Arabia Generic Pharmaceutical Products Market Report 2024-2031, Featuring Profiles of Key Players - GlobeNewswire Inc.

Oct 16, 2024
pulisher
Oct 15, 2024

Ophthalmic Disease Therapeutics Market Analysis by Age-related Macular Degeneration, Diabetic Macular Edema, & Other Retinal Disorders - GlobeNewswire Inc.

Oct 15, 2024
pulisher
Oct 14, 2024

Roche Wins FDA Nod For Breast Cancer Drug In First-Line Setting - Barchart

Oct 14, 2024
pulisher
Oct 11, 2024

Denmark Basal Cell Carcinoma Treatment Market Size & Outlook, 2030 - Grand View Research

Oct 11, 2024
pulisher
Oct 09, 2024

Europe Pruritus Therapeutics Market Size & Outlook, 2030 - Grand View Research

Oct 09, 2024
pulisher
Oct 09, 2024

Norway Aspergillosis Treatment Market Size & Outlook, 2030 - Grand View Research

Oct 09, 2024
pulisher
Oct 07, 2024

Precidian to List First ADRhedged Securities in the U.S. on Cboe - Traders Magazine

Oct 07, 2024
pulisher
Oct 03, 2024

IgA nephropathy Clinical Trials 2024 (Updated): FDA Approvals, Pipeline, Medication, Therapies, Treatment Market and Companies by DelveInsight - Barchart

Oct 03, 2024
pulisher
Oct 01, 2024

NVS: 3 European Stocks to Watch as the EU Economy Strengthens - StockNews.com

Oct 01, 2024
pulisher
Sep 25, 2024

Novartis Holds a Strong Branded Drug Portfolio Supporting Steady Long-term Growth - Morningstar

Sep 25, 2024
pulisher
Sep 21, 2024

Europe Alzheimers Therapeutics Market Size & Outlook, 2030 - Grand View Research

Sep 21, 2024
pulisher
Sep 20, 2024

Australia Alzheimers Therapeutics Market Size & Outlook, 2030 - Grand View Research

Sep 20, 2024
pulisher
Sep 18, 2024

Novartis Wins FDA Approval Of Kisqali For Early Breast Cancer - Barchart

Sep 18, 2024
pulisher
Sep 17, 2024

Novartis' Kisqali Lowers Risk Of Breast Cancer Recurrence By 28% - Barchart

Sep 17, 2024
pulisher
Sep 17, 2024

North America Immune Health Supplements Market Size & Outlook, 2030 - Grand View Research

Sep 17, 2024
pulisher
Sep 12, 2024

Top investors say Novartis AG ADR (NVS) ticks everything they need - SETE News

Sep 12, 2024
pulisher
Sep 11, 2024

Novartis lower as BofA downgrades on risks to valuation - MSN

Sep 11, 2024

Finanzdaten der Novartis Ag Adr-Aktie (NVS)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
drug_manufacturers_general MRK
$97.70
price up icon 1.40%
$286.05
price down icon 0.09%
drug_manufacturers_general PFE
$24.84
price down icon 0.38%
drug_manufacturers_general SNY
$47.64
price down icon 0.22%
$167.80
price up icon 0.93%
Kapitalisierung:     |  Volumen (24h):